Cell Therapy: Current Status and Future Directions (Molecular and Translational Medicine)
Language: English
Published by Humana Press, 2018
Series: Book 14 of 19 - Molecular and Translational Medicine
- Softcover
- New

Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
US$ 290.28
Quantity: 1 available
Add to basketItem description from seller
Seller Inventory # __3319860895
- Title
- Cell Therapy: Current Status and Future Directions (Molecular and Translational Medicine)
- Author
- Emerich, Dwaine F. (Editor) / Orive, Gorka (Editor)
- Publisher
- Humana Press
- Publication year
- 2018
- Condition
- Brand New
- Binding
- Paperback
- Language
- English
- ISBN 10
- 3319860895
- ISBN 13
- 9783319860893
- Item weight
- 0.71 kilograms
- Series
- Book 14 of 19: Molecular and Translational Medicine
This volume is designed to touch on the major areas where the field will make its greatest and most immediate clinical impacts. This text will provide a useful resource for physicians and researchers interested in the rapidly changing filed of cell therapy.
"Synopsis" may belong to another edition of this title.
About the Author
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | US$ 16.90 | US$ 33.79 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Shipping terms
Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.